clinical and regulatory development team that met with the FDA and gained agreement, via the Special Protocol Assessment (SPA) process, for the design and sizing of a single Phase III trial as the final efficacy study needed for marketing approval. In April 2011 the azimilide license and global development rights were purchased from BAT by Forest Labs, Inc. who will assume responsibility for the Phase III development program.